Please assess the completion status of the following clinical trial:

Trial Title: ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of adenocarcinoma of the colon or rectum, metastatic disease~* Wild-type KRAS tumor status~* Eastern Cooperative Oncology Group (ECOG) score of 0, 1 or 2~* Must have failed a prior regimen containing irinotecan for metastatic disease and a prior regimen containing oxaliplatin for metastatic disease~* Must have previously received a thymidylate synthase inhibitor (eg, fluorouracil, capecitabine, raltitrexed, or fluorouracil-uracil) at any point for treatment of colorectal cancer (CRC)~* Adequate hematologic, renal, hepatic and metabolic function~Exclusion Criteria:~* Symptomatic brain metastases requiring treatment~* Prior anti-epidermal growth factor receptor (EGFr) antibody therapy (eg, panitumumab or cetuximab) or treatment with small molecule EGFr inhibitors (eg, gefitinib, erlotinib, lapatinib)~* Antitumor therapy (eg, chemotherapy, hormonal therapy, immunotherapy, antibody therapy, radiotherapy), or investigational agent or therapy ≤ 30 days before randomization.~* Clinically significant cardiovascular disease~* Active infection requiring systemic treatment or any uncontrolled infection ≤14 days prior to randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetuximab (Type: ACTIVE_COMPARATOR): Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days.~Participants were treated until disease progression, intolerability, withdrawal of consent, or death.
- Panitumumab (Type: EXPERIMENTAL): Panitumumab 6 mg/kg IV every 14 days. Participants were treated until disease progression, intolerability, withdrawal of consent, or death.

Based on this trial design, predict the completion outcome and termination type (if applicable).